Ge Long Hui·2025-12-29 08:14Core Viewpoint - Shanghai Pharmaceuticals Holding Co., Ltd. plans to renew the framework agreement for daily related transactions with Yunnan Baiyao Group Co., Ltd. for the period from January 1, 2026, to December 31, 2026, with a sales cap of RMB 1.2 billion and a procurement cap of RMB 700 million [1] Group 1: Transaction Details - The sales cap for products sold by Shanghai Pharmaceuticals to Yunnan Baiyao is set at RMB 1.2 billion [1] - The procurement cap for products purchased by Shanghai Pharmaceuticals from Yunnan Baiyao is set at RMB 700 million [1] - The transaction involves amounts exceeding RMB 3 million and represents more than 0.5% but less than 5% of the latest audited net assets of Shanghai Pharmaceuticals, thus requiring board approval but not shareholder approval [1] Group 2: Shareholding Information - Yunnan Baiyao holds a 17.95% stake in Shanghai Pharmaceuticals, making it the second-largest shareholder [1] - According to the Shanghai Stock Exchange listing rules, Yunnan Baiyao is considered a related party to Shanghai Pharmaceuticals due to its significant shareholding [1]